Next 10 |
home / stock / bhc:cc / bhc:cc news
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with t...
2024-05-07 09:15:00 ET Summary Bausch Health Companies stock experienced a significant drop after posting its first-quarter results, missing expectations by 13 cents. The company's debt maturity profile raises concerns for investors, with a large amount of debt maturing in 2025 an...
2024-05-06 11:12:29 ET More on Bausch + Lomb Bausch + Lomb Corporation (BLCO) Q1 2024 Earnings Call Transcript Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript Bausch + Lomb Corporation 2023 Q4 - Results - Earnings Call Presentation Bausch + ...
2024-05-02 12:10:20 ET Bausch Health Companies [BHC] Q1 2024 Earnings Conference Call May 2, 2024, 8:00 a.m. ET Company Participants Thomas Appio - CEO John Barresi - Interim CFO Garen Sarafian - IR Conference Call Participants Glen Santangelo - Jeffe...
2024-05-02 07:25:58 ET More on Bausch Health Companies Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation Bausch Health Companies (BHC) Q4 2023 Earnings Call Transcript Bausch Health Companies Q1 2024 Earnings Preview Bausch Health gains af...
Kelt Exploration Ltd. (KEL:CA) is expected to report $0.07 for Q1 2024 Electrovaya Inc. (ELVA:CA) is expected to report $0.03 for Q2 2024 Western Copper and Gold Corporation (WRN:CA) is expected to report for Q1 2024 Galiano Gold Inc. (GAU:CA) is expected to report $-0.03 for Q1 2024 ...
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic 1 basis Year-over-year revenue growth in all segments on both a Reported and Organic 1 Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million Adjusted EBITDA Attributable t...
2024-05-01 11:30:14 ET More on Bausch Health Companies Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation Bausch Health Companies (BHC) Q4 2023 Earnings Call Transcript Bausch Health gains after appeals court affirms ruling in Norwich patent case (...
2024-04-25 12:33:40 ET More on Bausch + Lomb Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript Bausch + Lomb Corporation 2023 Q4 - Results - Earnings Call Presentation Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound Emer...
2024-04-24 11:01:15 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health sues Amneal Pharma over Xifaxan generic Amneal...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC:CC Stock Symbol:
TSXC Market:
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chronic liver disease increase, recognizing OHE is critical so that patients can work with t...
Kelt Exploration Ltd. (KEL:CA) is expected to report $0.07 for Q1 2024 Electrovaya Inc. (ELVA:CA) is expected to report $0.03 for Q2 2024 Western Copper and Gold Corporation (WRN:CA) is expected to report for Q1 2024 Galiano Gold Inc. (GAU:CA) is expected to report $-0.03 for Q1 2024 ...
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic 1 basis Year-over-year revenue growth in all segments on both a Reported and Organic 1 Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million Adjusted EBITDA Attributable t...